Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Advances in the treatment of primary and secondary immune deficiences

Advances in the treatment of primary and secondary immune deficiences Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9lBjFbu9i0DAnSw4JagSjiU on 10/30/2020 URRENT Advances in the treatment of primary and PINION secondary immune deficiences Srini Kaveri Intravenous immunoglobulins (IVIgs) are a thera- patients with autoimmune haemophilia. This effect peutic preparation of pooled normal polyspecific was attributed to the presence in IVIg of antiidiotypic human IgGs obtained from large numbers of antibodies against anti-Factor VIII autoantibodies [7]. healthy donors. The preparation contains anti- Subsequently, several other groups demonstrated bodies to nonself-antigens (microbial antigens), the existence of antiidiotypic antibodies against a antibodies to self-antigens (natural autoantibodies), wide range of pathogenic autoantibodies [6]. and antibodies that recognize other antibodies, also A proposed anti-inflammatory mechanism of known as antiidiotypic antibodies [1,2]. action for IVIg was an anticomplement scavenging In order to explain the therapeutic benefit effect. Indeed, binding of IVIg with complement conferred by IVIg in a large number of hetero- inhibits the generation of the C5b-9 membrane geneous disorders, several mutually nonexclusive attack complex and subsequent complement- mechanisms of action have been proposed, in the mediated tissue damage, such as that which occurs contexts of primary immune deficiency (PID), auto- in muscle microvasculature during dermatomyositis immunity, and inflammation. In PID, it is generally [8]. In the course http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy & Clinical Immunology Wolters Kluwer Health

Advances in the treatment of primary and secondary immune deficiences

Download PDF
28 pages

Loading next page...
 
/lp/wolters-kluwer-health/advances-in-the-treatment-of-primary-and-secondary-immune-deficiences-xVeL0CY1Wm

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0b013e328360c98d
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9lBjFbu9i0DAnSw4JagSjiU on 10/30/2020 URRENT Advances in the treatment of primary and PINION secondary immune deficiences Srini Kaveri Intravenous immunoglobulins (IVIgs) are a thera- patients with autoimmune haemophilia. This effect peutic preparation of pooled normal polyspecific was attributed to the presence in IVIg of antiidiotypic human IgGs obtained from large numbers of antibodies against anti-Factor VIII autoantibodies [7]. healthy donors. The preparation contains anti- Subsequently, several other groups demonstrated bodies to nonself-antigens (microbial antigens), the existence of antiidiotypic antibodies against a antibodies to self-antigens (natural autoantibodies), wide range of pathogenic autoantibodies [6]. and antibodies that recognize other antibodies, also A proposed anti-inflammatory mechanism of known as antiidiotypic antibodies [1,2]. action for IVIg was an anticomplement scavenging In order to explain the therapeutic benefit effect. Indeed, binding of IVIg with complement conferred by IVIg in a large number of hetero- inhibits the generation of the C5b-9 membrane geneous disorders, several mutually nonexclusive attack complex and subsequent complement- mechanisms of action have been proposed, in the mediated tissue damage, such as that which occurs contexts of primary immune deficiency (PID), auto- in muscle microvasculature during dermatomyositis immunity, and inflammation. In PID, it is generally [8]. In the course

Journal

Current Opinion in Allergy & Clinical Immunology – Wolters Kluwer Health

Published: Jul 1, 2013

There are no references for this article.